STAT Plus: Pfizer, with early but hopeful results, leaps into the race for a Duchenne gene therapy
RUBY WALLAU FOR STAT
The company’s gene therapy appeared to help children with the condition, but its side effects were severe in some clinical trial participants.
No hay comentarios:
Publicar un comentario